Catalyst Wire Dossier Catalyst Wire Dossier

LX211

· Lux Biosciences, Inc.
Drug timelines are a Plus or Pro feature.

3 regulatory and trial events tracked for LX211, covering 2012-06-22 to 2012-10-11. Get the full timeline:

Most recent: Clinical Trial Update: A Study of LX211 in Active Sight Threatening, Non-infectious Intermediate-, Anterior and Intermediate-, Posterior-, or Pan-Uveitis [Phase 3]

See pricing